APOE and Alzheimer disease: Large differences were observed within the ranges defined by indeterminate risk in the ADRC cohort including about 4-fold higher PET positivity and ApoE4 proteotype (APOE4 genotype) and 9-fold higher AD diagnosis, in the 0.150–0.159 range vs. the 0.160–0.169 range (Table 4).